+Vote!
Seeking Alpha (Free subscription) | 6 hours ago
Mike Huckman submits: Until the bearish call yesterday morning, shares of Alnylam (ALNY) were trading around $33 a share. But Leerink Swann, which specializes in biopharma/healthcare equities research, initiated coverage of the stock yesterday with an "Underperform" rating saying it should soon be worth less than half its value today. The analyst, Jonas Alsenas, a veterinarian, is setting...
1Vote!
Seeking Alpha (Free subscription) | 08/19/2008
Mike Huckman submits: Ads for flu vaccines have traditionally been confined to public service announcements (PSAs), health and media alerts. So, that's why I was surprised to see this colorful full-page ad in The New York Times last weekend for FluMist from AstraZeneca (AZN)/MedImmune. Complete Story »
+Vote!
Seeking Alpha (Free subscription) | 08/14/2008
Mike Huckman submits: The market cap of Dow component Johnson & Johnson (JNJ) is a whopping $200 billion. Abbott Labs (ABT) is valued at less than half that. But think of Abbott as a kind of mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products. Complete Story »
1Vote!
Seeking Alpha (Free subscription) | 08/14/2008
Mike Huckman submits: Before I get to my favorite biotech saga, there are noteworthy, if not newsworthy, press releases out this morning from two takeout targets. Genentech (DNA) put out a statement from the special independent board committee that's been appointed to handle the Roche (RHHBY.PK) buyout offer. To no one's surprise, the panel says 89 bucks a share ain't enough. But the...
